Sertraline Tablets

Key Dates
Due Date

-

Posted Date

-

Agency & Value
Agency

DLA TROOP SUPPORT

Contract Value

Not provided

Codes & Classification
Solicitation Number

SPE2D2-26-R-0002

NAICS

325412 - Pharmaceutical Preparation Manufacturing

Classification Code

6505

Additional Details
Set Aside

None

Place of Performance

-

SourceSAM
Documents2
The Defense Logistics Agency (DLA) Troop Support has issued Solicitation SPE2D2-26-R-0002, seeking qualified contractors for the supply of Sertraline Tablets. This procurement falls under the North American Industry Classification System (NAICS) code 325412, which pertains to Pharmaceutical Preparation Manufacturing, and is further classified under Product Service Code (PSC) 6505, indicating a focus on drugs and biologicals. The primary objective of this solicitation is to secure a reliable source of Sertraline Tablets, a pharmaceutical product commonly used in the treatment of depression and other mental health conditions. The intended outcome is to ensure the consistent availability of this medication for federal requirements, supporting the health and readiness of personnel served by DLA Troop Support. Contractors responding to this solicitation are expected to demonstrate the capability to manufacture and deliver Sertraline Tablets in accordance with all applicable federal standards and regulations. Key requirements likely include adherence to current Good Manufacturing Practices (cGMP), FDA approval for the product, and the ability to meet specified quality, packaging, and delivery timelines as detailed in the solicitation attachments. While the specific quantities and packaging configurations are not provided in the summary, interested parties should review the attached documents on the SAM.gov opportunity page for comprehensive technical and contractual requirements. The procurement is managed by DLA Troop Support, a federal office responsible for providing medical and pharmaceutical supplies to military and other government entities. The primary point of contact for this solicitation is Christopher Newman ([email protected], 445-737-7371), with Jason Wray ([email protected], 445-737-6304) listed as the secondary contact. Contractors are encouraged to direct any technical or administrative inquiries to these individuals. The solicitation was posted on September 12, 2025, and remains active, with responses due by December 17, 2025. The opportunity is accessible via the official SAM.gov portal at https://sam.gov/opp/38fc4d6470b84be1b0fb99669396416e/view, where two attachments are available for further review. Contractors should carefully examine these documents for detailed instructions, evaluation criteria, and submission requirements. No specific set-aside requirements or special considerations are indicated in the provided information. However, as with all federal procurements, compliance with applicable regulations and the ability to meet the government’s needs for quality, reliability, and timely delivery will be essential for successful participation. This opportunity is well-suited for pharmaceutical manufacturers with established capabilities in producing FDA-approved medications, robust quality assurance systems, and experience in fulfilling federal contracts. Interested parties should assess their alignment with the stated requirements and timelines to determine their suitability for this procurement.